Wellnex Life Signs Supple Agreement with GSK
Filed with ASX · · 2 pages · English
existing soft gel liquid analgesic, for a minimum term of three years. • GSK Consumer Healthcare is one of the world’s largest and leading global consumer healthcare companies • Wellnex Life will license and supply its innovative paracetamol soft gel liquid analgesic product to GSK. • This highlights the Company’s business model of bringing innovative and in-demand products to market in a capital-
In the deck
Earlier from Wellnex Life
- JV with WNX to Launch Organic A2 Infant Formula Range
- JV with AHF to Launch Organic A2 Infant Formula Range
- Appendix 4C and Quarterly Report for Dec 2021 Quarter
- Half Year Company Financial Update
- Wellnex Launches Pharmacy Own with CH2
Later from Wellnex Life
- Appendix 4C and Quarterly Report for March 2022 Quarter
- Wellnex Life to raise $7.5 million via Convertible Note
- Successful Completion of $6.2m Capital Raising via CN
- Wellnex Life forms Joint Venture with OneLife Botanicals
- Appendix 4C and Quarterly Report for June 2022 Quarter
Follow Wellnex Life into a list and get an email when it puts out news.
Follow Wellnex Life